Cancer immunotherapy has recently received a great deal of attention again due to the success of immune checkpoint blockade (ICB), which reactivates antitumor effector CD8+ T cell-mediated cancer cell death via the disruption of immune tolerance [52], although the response rate to ICB therapy remains at 20%–30% depending on cancer type [52]. The gene discussed is CD8A; the disease is cancer.